Elle Charnisky, a patient with stage IV HER2+ metastatic colorectal cancer (mCRC), joins a panel of healthcare professionals to discuss how HER2 alternations are detected and how patients with HER2+ mCRC are optimally treated to improve outcomes.
EP. 1: An Overview of Metastatic Colorectal Cancer (mCRC)
Tanios Bekaii-Saab, MD, provides a brief overview of the typical presentation and diagnosis of metastatic colorectal cancer.
EP. 2: A Patient’s Diagnosis with HER2+ Metastatic Colorectal Cancer
Patient Elle Charnisky shares the symptoms that led to her diagnosis of HER2+ metastatic colorectal cancer, and the online resources she used for education after.
EP. 3: The Importance of Molecular Testing in Metastatic Colorectal Cancer
Dr Tanios Bekaii-Saab explains the rarity of HER2+ metastatic colorectal cancer and how his clinical practice detects HER2 alterations.
EP. 4: Explaining Molecular Testing to Patients with Metastatic Colorectal Cancer
Elle Charnisky describes her experience with molecular testing, and Nurse Practitioner Deanna Griffie details how she explains testing to patients with metastatic colorectal cancer.
EP. 5: Barriers to Molecular Testing in Metastatic Colorectal Cancer
Tanios Bekaii-Saab, MD, explains the barriers to molecular testing for patients with metastatic colorectal cancer, and how they can be addressed.
EP. 6: First-Line Treatment Options for HER2+ Metastatic Colorectal Cancer
Dr Bekaii-Saab provides an overview of the first-line treatment options in metastatic colorectal cancer, and the factors that impact treatment decision-making.
EP. 7: A Patient’s Treatment Journey with HER2+ Metastatic Colorectal Cancer
Patient Elle Charnisky shares her experience with a conventional chemotherapy treatment for her HER2+ metastatic colorectal cancer before transitioning to targeted therapies.
EP. 8: Appropriate Patient Selection for Patients with HER2+ Metastatic Colorectal Cancer for Anti-HER2 Therapies
Dr Tanios Bekaii-Saab describes for which patient groups he would use anti-HER2 therapies as a second-line treatment for HER2+ metastatic colorectal cancer.
EP. 9: Toxicity Management with Trastuzumab Deruxtecan in HER2+ Metastatic Colorectal Cancer
Deanna Griffie, MSN, AGNP-BC, shares how common toxicities in patients with HER2+ mCRC being treated with trastuzumab deruxtecan are treated at her clinic.
EP. 10: The MOUNTAINEER Trial of Tucatinib for Treatment of HER2+ mCRC
John Strickler, MD, details the design and outcomes of the MOUNTAINEER trial investigating the combination treatment of tucatinib with trastuzumab for HER2+ metastatic colorectal cancer.
EP. 11: Recap: Discussing Treatment Updates in CRC With a Patient Advocate
EP. 12: Managing Toxicities with Tucatinib in Patients with HER2+ mCRC
Deanna Griffie, MSN, AGNP-BC, and Tanios Bekaii-Saab, MD, explain how they manage the toxicities of tucatinib in patients with HER2+ mCRC, and how they educate patients on what to expect.
EP. 13: Advice on HER2+ Metastatic Colorectal Cancer for Patients and Caregivers
Elle Charnisky, a patient with HER2+ metastatic colorectal cancer, and Deanne Griffie, a nurse practitioner, share advice for patients and caregivers living with HER2+ mCRC.
EP. 14: Unmet Needs in Patient Care for Metastatic Colorectal Cancer
The panel closes by highlighting currently unmet needs in the treatment and management of metastatic colorectal cancer.
2 Clarke Drive Cranbury, NJ 08512